Chronic Plaque Psoriasis Clinical Trial
— DERMIS-1Official title:
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis
Verified date | December 2022 |
Source | Arcutis Biotherapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult participants with 2 to 20% body surface area (BSA) of CPP.
Status | Completed |
Enrollment | 439 |
Est. completion date | November 16, 2020 |
Est. primary completion date | November 16, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria: - Participants legally competent to sign and give informed consent and if appropriate assent as required by local laws - Males and females ages 2 years and older (inclusive) - Clinical diagnosis of psoriasis vulgaris of at least 6 months duration (3 months for children) as determined by the Investigator - Females of childbearing potential (FOCBP) must have a negative pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial. - In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis. - Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator. Exclusion Criteria: - Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED. - Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding. - Previous treatment with ARQ-151 or its active ingredient - Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator. - Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product - Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation |
Country | Name | City | State |
---|---|---|---|
Canada | Arcutis Biotherapeutics Clinical Site 132 | Calgary | Alberta |
Canada | Arcutis Biotherapeutics Clinical Site 103 | London | Ontario |
Canada | Arcutis Biotherapeutics Clinical Site 122 | Markham | Ontario |
Canada | Arcutis Biotherapeutics Clinical Site 133 | Mississauga | Ontario |
Canada | Arcutis Biotherapeutics Clinical Site 107 | Montreal | Quebec |
Canada | Arcutis Biotherapeutics Clinical Site 140 | Ottawa | Ontario |
Canada | Arcutis Biotherapeutics Clinical Site 109 | Peterborough | Ontario |
Canada | Arcutis Biotherapeutics Clinical Site 126 | Québec | Quebec |
Canada | Arcutis Biotherapeutics Clinical Site 106 | Waterloo | Ontario |
United States | Arcutis Biotherapeutics Clinical Site 111 | Baton Rouge | Louisiana |
United States | Arcutis Biotherapeutics Clinical Site 101 | Brighton | Massachusetts |
United States | Arcutis Biotherapeutics Clinical Site 116 | Clinton Township | Michigan |
United States | Arcutis Biotherapeutics Clinical Site 104 | College Station | Texas |
United States | Arcutis Biotherapeutics Clinical Site 119 | Dallas | Texas |
United States | Arcutis Biotherapeutics Clinical Site 118 | Delray Beach | Florida |
United States | Arcutis Biotherapeutics Clinical Site 128 | Duncansville | Pennsylvania |
United States | Arcutis Biotherapeutics Clinical Site 129 | East Windsor | New Jersey |
United States | Arcutis Biotherapeutics Clinical Site 127 | Encinitas | California |
United States | Arcutis Biotherapeutics Clinical Site 113 | Exton | Pennsylvania |
United States | Arcutis Biotherapeutics Clinical Site 124 | Fairborn | Ohio |
United States | Arcutis Biotherapeutics Clinical Site 112 | Fremont | California |
United States | Arcutis Biotherapeutics Clinical Site 115 | High Point | North Carolina |
United States | Arcutis Biotherapeutics Clinical Site 120 | Irvine | California |
United States | Arcutis Biotherapeutics Clinical Site 131 | Miami | Florida |
United States | Arcutis Biotherapeutics Clinical Site 121 | New York | New York |
United States | Arcutis Biotherapeutics Clinical Site 137 | Ocala | Florida |
United States | Arcutis Biotherapeutics Clinical Site 134 | Oklahoma City | Oklahoma |
United States | Arcutis Biotherapeutics Clinical Site 135 | Pittsburgh | Pennsylvania |
United States | Arcutis Biotherapeutics Clinical Site 114 | Plainfield | Illinois |
United States | Arcutis Biotherapeutics Clinical Site 139 | Reno | Nevada |
United States | Arcutis Biotherapeutics Clinical Site 130 | Rochester | New York |
United States | Arcutis Biotherapeutics Clinical Site 125 | Rockville | Maryland |
United States | Arcutis Biotherapeutics Clinical Site 138 | Rockville | Maryland |
United States | Arcutis Biotherapeutics Clinical Site 102 | Rolling Meadows | Illinois |
United States | Arcutis Biotherapeutics Clinical Site 110 | San Antonio | Texas |
United States | Arcutis Biotherapeutics Clinical Site 117 | San Antonio | Texas |
United States | Arcutis Biotherapeutics Clinical Site 123 | San Diego | California |
United States | Arcutis Biotherapeutics Clinical Site 136 | San Francisco | California |
United States | Arcutis Biotherapeutics Clinical Site 105 | Sanford | Florida |
United States | Arcutis Biotherapeutics Clinical Site 108 | Stony Brook | New York |
Lead Sponsor | Collaborator |
---|---|
Arcutis Biotherapeutics, Inc. |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 | The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented (observed data only) for each arm. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a =2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity. | Baseline (Day 1) and Week 8 | |
Secondary | Time to Achieve Psoriasis Area Severity Index-50 (PASI-50) | The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The time to achieve PASI-50 (defined as a 50% reduction from baseline in PASI score) is presented, and is based on observed data only. | From start of treatment to achievement of PASI-50 or study completion/early termination (maximum duration = 121 days) | |
Secondary | Number of Participants Achieving Psoriasis Area Severity Index 75 (PASI-75) | The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-75 (defined as a 75% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only. | Baseline (Day 1) and Week 8 | |
Secondary | Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90) | Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease) [higher scores indicate greater symptom severity]. The number of participants achieving PASI-90 (defined as a 90% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only. | Baseline (Day 1) and Week 8 | |
Secondary | Number of Participants Achieving Intertriginous IGA (I-IGA) Success at Week 8 | The number of participants achieving I-IGA success at Week 8 is presented. Success is defined as achievement of I-IGA score of 0 ('clear') or 1 ('almost clear') at Week 8 PLUS a =2-grade improvement in score from Baseline. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis in the intertriginous area, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater symptom severity. Participant counts are based on observed data only. | Baseline (Day 1) and Week 8 | |
Secondary | Number of Participants Achieving Score of 'Clear' in I-IGA at Week 8 | The number of participants achieving an IGA score of 0 ('clear') at Week 8 is presented (observed data only) for each arm. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'); higher scores indicate greater symptom severity. | Week 8 | |
Secondary | Number of Participants Achieving Worst Itch Numerical Rating Score (WI-NRS) Success | The number of participants achieving success in WI-NRS is presented. Success is defined as achievement of a = 4-point reduction in WI-NRS pruritus score in participants with WI-NRS pruritus score = 4 at baseline. The WI-NRS is a 10 point scale ranging from 0 ('no itch') to 10 ('worst itch imaginable'), with higher scores indicating greater symptoms severity. Results are based on observed data only. | Baseline (Day 1) and Weeks 2, 4, and 8 | |
Secondary | Change From Baseline in Psoriasis Symptoms Diary (PSD) Score | The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The least squares (LS) mean (95% CI) change in PSD total score relative to baseline is presented for each treatment arm, with decreases from baseline indicating symptom improvement. | Weeks 4 and 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03598790 -
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT00799877 -
Chronic Plaque Psoriasis (Ps) Registry
|
||
Completed |
NCT02581345 -
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
|
Phase 3 | |
Withdrawn |
NCT01200264 -
Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy
|
Phase 2 | |
Terminated |
NCT00972543 -
Raptiva in Palm and Sole Psoriasis
|
Phase 4 | |
Not yet recruiting |
NCT00707070 -
Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis
|
Phase 4 | |
Completed |
NCT00539929 -
Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis
|
Phase 2 | |
Completed |
NCT02852967 -
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT00770965 -
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
|
Phase 2 | |
Active, not recruiting |
NCT06011733 -
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT00245765 -
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
|
Phase 2 | |
Completed |
NCT00673556 -
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
|
Phase 3 | |
Terminated |
NCT00844363 -
Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris
|
N/A | |
Completed |
NCT00574249 -
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
|
Phase 3 | |
Completed |
NCT00512187 -
Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
|
Phase 4 | |
Completed |
NCT02570750 -
The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis
|
||
Completed |
NCT00438360 -
Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis
|
Phase 3 | |
Active, not recruiting |
NCT03897075 -
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
|
Phase 3 | |
Completed |
NCT01358578 -
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
|
Phase 3 | |
Completed |
NCT03536884 -
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 3 |